132 related articles for article (PubMed ID: 1708398)
1. Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans.
Cryz SJ; Cross AS; Sadoff JC; Wegmann A; Que JU; Fürer E
J Infect Dis; 1991 May; 163(5):1040-5. PubMed ID: 1708398
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.
Cryz SJ; Cross AS; Sadoff JC; Fürer E
Infect Immun; 1990 Feb; 58(2):373-7. PubMed ID: 2105272
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Que JO; Cross AS; Fürer E
Vaccine; 1995 Apr; 13(5):449-53. PubMed ID: 7639013
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
[TBL] [Abstract][Full Text] [Related]
5. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
Cryz SJ; Fürer E; Sadoff JC; Germanier R; Pastan I; Willingham MC; FitzGerald DJ
Rev Infect Dis; 1987; 9 Suppl 5():S644-9. PubMed ID: 3120274
[TBL] [Abstract][Full Text] [Related]
6. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.
Cryz SJ; Lang AB; Sadoff JC; Germanier R; Fürer E
Infect Immun; 1987 Jul; 55(7):1547-51. PubMed ID: 3110065
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Que JU
Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines.
Konadu E; Robbins JB; Shiloach J; Bryla DA; Szu SC
Infect Immun; 1994 Nov; 62(11):5048-54. PubMed ID: 7927787
[TBL] [Abstract][Full Text] [Related]
9. Clearance of Pseudomonas aeruginosa from normal rat lungs after immunization with somatic antigens or toxin A.
Johansen HK; Cryz SJ; Høiby N
APMIS; 1994 Jul; 102(7):545-53. PubMed ID: 7917224
[TBL] [Abstract][Full Text] [Related]
10. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults.
Konadu EY; Parke JC; Tran HT; Bryla DA; Robbins JB; Szu SC
J Infect Dis; 1998 Feb; 177(2):383-7. PubMed ID: 9466525
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers.
Cross A; Artenstein A; Que J; Fredeking T; Furer E; Sadoff JC; Cryz SJ
J Infect Dis; 1994 Oct; 170(4):834-40. PubMed ID: 7523536
[TBL] [Abstract][Full Text] [Related]
12. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.
Cryz SJ; Sadoff JC; Fürer E
Infect Immun; 1988 Jul; 56(7):1829-30. PubMed ID: 2454893
[TBL] [Abstract][Full Text] [Related]
13. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Sadoff JC; Germanier R
Antibiot Chemother (1971); 1987; 39():249-55. PubMed ID: 3118786
[No Abstract] [Full Text] [Related]
14. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis.
Schaad UB; Lang AB; Wedgwood J; Ruedeberg A; Que JU; Fürer E; Cryz SJ
Lancet; 1991 Nov; 338(8777):1236-7. PubMed ID: 1682645
[TBL] [Abstract][Full Text] [Related]
15. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier.
Lebens M; Holmgren J
Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models.
van den Dobbelsteen GPJM; Faé KC; Serroyen J; van den Nieuwenhof IM; Braun M; Haeuptle MA; Sirena D; Schneider J; Alaimo C; Lipowsky G; Gambillara-Fonck V; Wacker M; Poolman JT
Vaccine; 2016 Jul; 34(35):4152-4160. PubMed ID: 27395567
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
[TBL] [Abstract][Full Text] [Related]
18. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Lang A; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Schaad U
Behring Inst Mitt; 1997 Feb; (98):345-9. PubMed ID: 9382759
[TBL] [Abstract][Full Text] [Related]
19. [Protective polysaccharide-protein artificial antigens from O-specific polysaccharides of Pseudomonas aeruginosa and its exotoxin A].
Dmitriev BA; Kul'shin VA; Antsiferova NG; Vovk VA; Moroz AF
Dokl Akad Nauk SSSR; 1988; 298(5):1277-80. PubMed ID: 2454182
[No Abstract] [Full Text] [Related]
20. Clinical Studies of Escherichia coli O157:H7 Conjugate Vaccines in Adults and Young Children.
Szu SC; Ahmed A
Microbiol Spectr; 2014 Dec; 2(6):. PubMed ID: 26104443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
